Arcus Biosciences to Participate in Two Upcoming Investor Conferences in September 2022

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences:

Citi 17th Annual BioPharma Conference
Date: Wednesday, September 7th, 2022
Location: Boston, MA
Format: 1-on-1 meetings only

Morgan Stanley 20th Annual Global Healthcare Conference
Date: Monday, September 12th , 2022 at 12:30 p.m. ET
Location: New York, NY
Format: Fireside Chat

A live webcast of the fireside chat will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at A replay of the webcast will be available following the live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor) and most recently, HIF-2a. For more information about Arcus Biosciences’ clinical and pre-clinical programs, please visit or follow us on Twitter.

View source version on


Media Inquiries
Holli Kolkey
VP of Corporate Communications
(650) 922-1269

Investor Inquiries
Pia Banerjee
Head of Investor Relations & Strategy
(617) 459-2006

Source: Arcus Biosciences

Powered by Business Wire

View this news release online at:

Back to news